TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05454436

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus tract healing in single or multi visit with single cone technique with bioceramic sealer
Description: Investigators will see the healing rate between single visit and multi visit with single cone technique with bioceramic sealer .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus tract healing in single or multi visit with single cone technique with bioceramic sealer
Description: Investigators will see the healing rate between single visit and multi visit with single cone technique with bioceramic sealer .
Study: NCT06373471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) and treatment
Description: CGA and treatment is as an outpatient evaluation by a geriatric medical specialist and nurse. Specific CGA components in this study include:~* Assessment of comorbidity and treatments~* Review of medications including potential adjustment~* Assessment of current symptoms and health related issues including geriatric syndromes such as depression, dementia, delirium, nutritional problems, falls and fatigue~* Objective examination including blood tests and electrocardiogram~* Assessment of activities of daily living (ADL) and instrumental ADL through standardized questionnaires~* Assessment of domestic conditions, including need for assistance~* Assessment of physical function Based on findings, the geriatrician will initiate relevant interventions and follow-up as required
Study: NCT05997433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 7days bismuth quadruple
Description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid\*7days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 14 days bismuth quadruple
Description: Amoxicillin 1000mg bid+ Tetracycline 500mg qid+ Bismuth + Tegoprazan 50mg bid\*14days
Study: NCT05876091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaping
Description: Undergo vape puffing regimen

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of saliva samples and oral cell samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Administer Quesitonnaire
Study: NCT05973097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: total glucosides of paeony treatment
Description: Total glucosides of paeony capsules were given 0.6 g once, 3 times a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: photodynamic therapy treatment
Description: Cover the lesion with photosensitizer and fix it. Remove the photosensitizer and treat with laser diode.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glucosides of paeony and photodynamic therapy combined treatment
Description: Glucosides of paeony and photodynamic therapy are combined for the treatment
Study: NCT06306079

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral Wedge insole
Description: Insoles with lateral wedges are placed in patients' shoes to control biomechanical knee loading on the medial side of the knee. Insoles with lateral wedges are designed to be thinner on the inside (medially of the foot) and thicker on the outside (laterally of the foot) to relieve knee biomechanical loading parameters.
Study: NCT03870516

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve replacement
Description: Replacing the diseased mitral valve in cases with severe mitral regurgitation with a prosthetic valve.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Mitral valve replacement
Description: Replacing the diseased mitral valve in cases with severe mitral regurgitation with a prosthetic valve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Speckle tracking echocardiography
Description: We will perform Speckle tracking echocardiography in order to identify patients with early subclinical left ventricular or left atrial dysfunction and refer them to surgery, Then after surgery, speckle tracking echocardiography will be performed for all patients to assess improvement of left atrial (conduit, reservoir and booster contractile functions) and left ventricular (global longitudinal strain) function

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Speckle tracking echocardiography
Description: We will perform Speckle tracking echocardiography in order to identify patients with early subclinical left ventricular or left atrial dysfunction and refer them to surgery, Then after surgery, speckle tracking echocardiography will be performed for all patients to assess improvement of left atrial (conduit, reservoir and booster contractile functions) and left ventricular (global longitudinal strain) function
Study: NCT05443893

Intervention type: DEVICE
Intervention: Application Research of key points detection technology
Description: Artificial intelligence human key point detection model mainly has traditional algorithm, top-down algorithm and bottom-up algorithm three methods, three methods have advantages. This project will comprehensively use the above three methods to conduct algorithm and parameter debugging in the public data set and test in the private data set, so as to obtain the most suitable human key point recognition method for gait analysis

Intervention type: DEVICE
Intervention: Application Research of key points detection technology
Description: Artificial intelligence human key point detection model mainly has traditional algorithm, top-down algorithm and bottom-up algorithm three methods, three methods have advantages. This project will comprehensively use the above three methods to conduct algorithm and parameter debugging in the public data set and test in the private data set, so as to obtain the most suitable human key point recognition method for gait analysis
Study: NCT06013657

Intervention type: PROCEDURE
Intervention: Liver Resection
Description: Resection of a part of the liver afflicted by hepatocellular carcinoma
Study: NCT05281796

Intervention type: DIAGNOSTIC_TEST
Intervention: GCF obtaining
Description: GCF sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)

Intervention type: DIAGNOSTIC_TEST
Intervention: GCF obtaining
Description: GCF sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)

Intervention type: DIAGNOSTIC_TEST
Intervention: GCF obtaining
Description: GCF sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)

Intervention type: DIAGNOSTIC_TEST
Intervention: saliva obtaining
Description: Saliva sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)

Intervention type: DIAGNOSTIC_TEST
Intervention: saliva obtaining
Description: Saliva sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)

Intervention type: DIAGNOSTIC_TEST
Intervention: saliva obtaining
Description: Saliva sample collection by Enzyme-Linked Immunosorbent Assay (ELISA)
Study: NCT06387849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: women enrolled in the experimental group received aromatherapy with lavender essential oil (EO) through dry inhalation (inhalation via a cotton support soaked in a few drops of EO)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: women enrolled in the placebo group received ihaled a cotton support soaked in a few drops of distilled water
Study: NCT05563922

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Total Neoadjuvant Chemoradiotherapy
Description: Radiotherapy：45Gy/25F+Boost 50Gy/25F. A total of 45 Gy, 25 fractions of 1.8 Gy, 5 fractions a week~CapOx:~Capecitabine 1000mg / m² po bid (1-14 days, 21 days a cycle) Oxaliplatin 130mg / m2 igtt(Day 1, 21 days a cycle) TEM or endoscopic local resection
Study: NCT05546294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobic and home exercise
Description: A total of 20 sessions of aerobic exercises using bicycle ergometer, five times a week and once a day for four weeks, were applied to the patients.Maximum heart rate was calculated for each subject (220 - age) and a heart rate monitor will be used to follow subjects' heart rate during aerobic exercise.~Then the patients were showed a daily home exercise program to apply once a day at their home.~As a daily home exercise program:ROM exercises and strengthening exercises for major muscle groups (such as abdominal muscles, erector spinae, hamstring, quadriceps, hip flexors, strengthening exercises for all extremities) were showed.~At the beginning of the treatment and at the end of the treatment (4th week), serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken from the RA patients in the early morning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise
Description: The patients were showed only a daily home exercise program to apply once a day at their home.~As a daily home exercise program:ROM exercises and strengthening exercises for major muscle groups (such as abdominal muscles, erector spinae, hamstring, quadriceps, hip flexors, strengthening exercises for all extremities) were showed.~At the beginning of the treatment and at the end of the treatment (4th week), serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken from the RA patients in the early morning.

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy control group
Description: Serum BDNF and irisin levels will be tested using the ELISA kit, with blood samples taken only once from healthy control group in the early morning. It will be checked whether there is a difference between the basal serum BDNF and irisin levels of rheumatoid arthritis patients and healthy control group.
Study: NCT05009927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib tablets
Description: Imatinib interruption
Study: NCT04747093

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-ITNK cells
Description: CAR-ITNK cells will be infused over 10-15 minutes on Day 0.
Study: NCT04843215

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of omentectomy
Description: Experimental group D2 radical gastrectomy with partial omentectomy. Partial omentectomy with preservation of the greater omentum at \>3 cm from the gastroepiploic arcade.Control group with total omentectomy.
Study: NCT06456528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0911
Description: QL0911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL0911 plus Placebo
Description: QL0911 plus Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04844684

Intervention type: OTHER
Intervention: Blood and urine collection
Description: Blood sampling urine collections before RYGP and 1 month and 1 year after.
Study: NCT05691049

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HCC_45
Description: Dosage form: HCC_45 is a resorbable medical device 2 ml non-pyrogenic pre-filled syringe, containing 2 ml of hyaluronic acid for intradermal use.~The principal component of the medical device is Hyaluronic Acid of non-animal origin, produced by bacterial fermentation.
Study: NCT06162000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The group that will use the developed software in case studies
Description: In the study, a case study will be conducted with students in the control and intervention groups once a week for four weeks.~Students in the control group will be given printed cases and asked to prepare care plans on ready-made paper templates.~Case preparation activities of the students in the intervention group will be carried out in line with the software planned to be developed. Before the case preparation activities begin, an information/promotional meeting will be held regarding the use of the application planned to be developed. Students will log in to the application with their e-mail addresses and the password they will choose when they first log in. Students will be asked to review the software and questions regarding usage will be answered. Students will record patient data in the cases into KSDE-HBPYS and prepare care plans with the software. At the end of the case studies, a posttest case and Clinical Decision Making Scale will be applied to both groups.
Study: NCT05407909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX2001
Description: SYHX2001 tablets, oral
Study: NCT06736496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Description: patients will receive : nalbuphine administered at a dose of 0.2 mg / kg IV bolus dose before induction and intermittent doses of 0.5 mg/kg if MAP and HR greater than 20% of the base line value.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: patients will receive : Dexmedetomidine infusion at rate of 0.5mcg/kg/h initiated 10 min before induction and ketamine iv bolus dose of 0.35 mg/kg and Lidocaine iv bolus dose of 1mg/kg administrated before skin incision.
Study: NCT06736314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a removable titanium clip
Description: The removable titanium clip is a new type of titanium clip that offers advantages such as easy operation and convenient disassembly.
Study: NCT06736223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357
Description: ITF2357 (INNM Givinostat hydrochloride Monohydrate), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357
Description: ITF2357 (INNM Givinostat hydrochloride Monohydrate), single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357
Description: ITF2357 (INNM Givinostat hydrochloride Monohydrate), single dose
Study: NCT05470946

Intervention type: DEVICE
Group type: OTHER
Intervention: Double balloon enteroscopy
Description: Double balloon enteroscopy (EN-580T, Fujifilm, Japan)
Study: NCT05518227

Intervention type: DEVICE
Intervention: The Clareon™ PanOptix™ Trifocal (toric and non-toric models)
Description: Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)
Study: NCT04206995

Intervention type: OTHER
Intervention: Solid Phase Microextraction (SPME)
Description: A SPME fibre is held directly above skin cancer, or healthy skin for a period of less than 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.

Intervention type: OTHER
Intervention: Absorptive patch
Description: An adsorptive patch, covering skin cancer and healthy skin sites will be applied for a period of maximum 30 minutes to capture VOCs. No drug will be used. This is to investigate the capability of the technique in capturing VOCs.
Study: NCT06235814

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Molecular Analysis for Thyroid Resection
Description: Protocol for Operative Management based on Molecular Risk Classifier~Patients will have a televisit (i.e. video-visit) with us in 2 weeks once the ThyroSeq molecular analysis results. In that visit, we will discuss the operation the patient will receive, including the risks and benefits of the operation. Operative management will be dictated by the molecular results listed below:~* Low molecular-risk: thyroid lobectomy~* High molecular-risk: total thyroidectomy~* Intermediate molecular-risk: randomization to thyroid lobectomy or total thyroidectomy~Of note, the respective operations for the low and high molecular-risk groups are standard of care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Molecular Analysis for Thyroid Resection
Description: Protocol for Operative Management based on Molecular Risk Classifier~Patients will have a televisit (i.e. video-visit) with us in 2 weeks once the ThyroSeq molecular analysis results. In that visit, we will discuss the operation the patient will receive, including the risks and benefits of the operation. Operative management will be dictated by the molecular results listed below:~* Low molecular-risk: thyroid lobectomy~* High molecular-risk: total thyroidectomy~* Intermediate molecular-risk: randomization to thyroid lobectomy or total thyroidectomy~Of note, the respective operations for the low and high molecular-risk groups are standard of care.
Study: NCT05490173

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exosomes derived from mesenchymal stromal cells (MSCs)
Description: Exosomes derived from mesenchymal stromal cells (MSCs) will be administered intranasal in ELBW infants
Study: NCT05707832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B cholesteryl Sulfate Complex for Injection
Description: Intravenous injection (IV), once a day after reaching the recommended dose of 3.0-4.0 mg/kg for treatment. Subjects will receive ABCD intravenous therapy for at least 2 weeks, and the longest course of treatment will not exceed 6 weeks.
Study: NCT04650282

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lidocaine in SphenoCath device
Description: Participants will receive 2.5 cc of lidocaine 1% solution intranasally via a SphenoCath device into each nares.The portion of the procedure involving this device lasts approximately 30-60 seconds.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution in SphenoCath device
Description: Participants will receive saline solution via a SphenoCath device into each nares. The portion of the procedure involving this device lasts approximately 30-60 seconds.
Study: NCT05495139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease
Description: This study includes 3 phases; screening period, procedural period, and a follow-up period. Following a 2-week screening period, subjects will be treated with the Gastric Bypass Stent System implanted under gastroscopy (Visit 2; Day 0). Following a 6-month treatment period, the device is removed, and subjects are followed for 6 months. In total subject participation will last for approximately 12 months.
Study: NCT04823611

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part A:Placebo
Description: Placebo solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A:AZD8233
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part B:Placebo
Description: Placebo solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B:AZD8233
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B:AZD8233
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Part C: Placebo
Description: Placebo solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part C: AZD8233
Description: PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
Study: NCT06013592

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 0 kcal liquid meal
Description: Flavoured water, given as one meal at one study visit only

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 0 kcal liquid meal
Description: Flavoured water, given as one meal at one study visit only

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 600 kcal liquid meal
Description: Fortisip Compact Vanilla, given as one meal at one study visit only

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 600 kcal liquid meal
Description: Fortisip Compact Vanilla, given as one meal at one study visit only

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 900 kcal liquid meal (only for group without obesity)
Description: Fortisip Compact Vanilla, given as one meal at one study visit only

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1200 kcal liquid meal
Description: Fortisip Compact Vanilla, given as one meal at one study visit only

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1200 kcal liquid meal
Description: Fortisip Compact Vanilla, given as one meal at one study visit only

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1800 kcal liquid meal (only for group with obesity)
Description: Fortisip Compact Vanilla, given as one meal at one study visit only
Study: NCT05044689

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire containing questions regarding diet, physical activity, past medical history and life style practices.

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire containing questions regarding diet, physical activity, past medical history and life style practices.

Intervention type: DEVICE
Intervention: Bioimpedance/Body Composition Unit
Description: Patients will provide information on body composition through the use of a bioimpedance machine which measures the body mass index, fat and total body water.

Intervention type: DEVICE
Intervention: Bioimpedance/Body Composition Unit
Description: Patients will provide information on body composition through the use of a bioimpedance machine which measures the body mass index, fat and total body water.
Study: NCT04763369

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of stem cells in sub-tenon space of eye for the management of retinitis pigmentosa
Description: Cultured stem cells will be injected in the sub-tenon space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of stem cells in suprachoroidal space of eye for the management of Retinitis Pigmentosa
Description: Cultured stem cells will be injected in the suprachoroidal space of eye and patients will be monitored and evaluated for outer retinal thickness, early treatment of diabetic retinopathy study visual acuity, visual field sensitivity, fundus photography, amplitudes of multifocal electroretinogram and implicit times of multifocal electroretinogram at baseline (day 0) and days 30, 60, 90, 180, 270 and 360.